KOL & payer market research for small molecule in aortic valve stenosis

Challenge A European investor required due diligence on a lead preclinical candidate being developed by a biotech company for the treatment and prevention of aortic valve stenosis (AVS). Alacrita was...
Learn More

Providing due diligence in inflammation and fibrosis area

Challenge: An innovation fund interested in a research institute developing proprietary mAbs against a novel liver disease target, asked Alacrita to conduct due diligence on the development of this...
Learn More

Investor due diligence for a live biotherapeutic product

Challenge: A developer of live biotherapeutic products (LBP) derived from stool donations had a lead product in phase 2 clinical trials for metabolic pathology secondary to hepatic pathology. An...
Learn More

Due diligence on a computational chemistry software for a private equity firm

Challenge: A generalist private equity firm was considering an investment in a computational chemistry company, and required an evaluation of the company’s software suite as part of its due diligence...
Learn More

Due diligence on a series of investments in oncology and genetic diseases

Challenge: A European investor required due diligence support to appraise the attractiveness of a series of potential investments. The technologies included a theranostic agent, a DNA damage response...
Learn More

Clinical and regulatory due diligence of an asset targeting pre-term birth complications

Challenge: Our client was a European mid-size pharmaceutical company considering an investment in a clinical-stage company developing an asset for multiple indications associated with pre-term birth...
Learn More

Due Diligence on DNA damage response assets

Challenge: An oncology company with a ‘hub and spoke’ structure wished to commission an expert third-party due diligence on one of its spin-out companies in support of its next investment round. The...
Learn More

Due diligence on life cycle management strategies for acute care assets

Challenge: Our client was a pharmaceutical company considering an acquisition of two approved assets and required expert due diligence on the clinical, regulatory and manufacturing aspects of the two...
Learn More

Technical and commercial due diligence of antibody against metastatic cancers

Challenge: A VC firm was exploring investment in a spin-out company with an antibody targeted at metastatic cancer indications. Before committing to the financing round, the investor required...
Learn More

Pre-DD on re-purposed ophthalmology product

Challenge: A private investment firm was interested in a European drug re-purposing company and asked Alacrita to perform top-level due diligence to help the firm decide whether it wanted to proceed...
Learn More

Due diligence for a microbiome therapeutic

Challenge: Our client, a mid-cap pharma, was planning to extend its portfolio in the gastrointestinal (GI) disease space. It was considering microbiome-based approaches, specifically live...
Learn More

Due diligence for in-licensing opportunities in oncology

Challenge: A lean pharma company reached out to Alacrita for due diligence support regarding three oncology assets of interest, prior to entering into licensing negotiations. The client requested an...
Learn More
1 2 3 4 5 ... 9